Please assess the completion status of the following clinical trial:

Trial Title: Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight ≥ 88 lbs and ≤ 275 lbs~* Documented chronic Hepatitis C (CHC) GT2 or GT3 infection~* No known cirrhosis~* Agrees to use two acceptable methods of birth control during study and through 6 months after last dose of study drug~* Chest X-ray within the last 6 months~* Eye exam within the last 6 months~Exclusion Criteria:~* Known to be human immunodeficiency virus (HIV) positive or co-infected with active hepatitis B virus (positive for Hepatitis B surface antigen)~* Prior approved or investigational treatment for hepatitis C~* Evidence of hepatocellular carcinoma~* Diabetic and/or high blood pressure with clinically significant eye exam findings~* Pre-existing psychiatric condition~* Clinical diagnosis of abuse of certain substances within specified timeframes~* Known medical condition that could interfere with participation~* Active or suspected cancer within the last 5 years~* Female who is pregnant, breastfeeding, or expecting to conceive or donate eggs~* Male who is planning to impregnate partner or donate sperm~* Male with a pregnant female partner~* Chronic hepatitis not caused by HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Grazoprevir 200 mg + Peg-IFN + RBV (Type: EXPERIMENTAL): Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
- Grazoprevir 400 mg + Peg-IFN + RBV (Type: EXPERIMENTAL): Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
- Placebo + Peg-IFN + RBV (Type: PLACEBO_COMPARATOR): Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
- Grazoprevir 800 mg + Peg-IFN + RBV (Type: EXPERIMENTAL): Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).